



CUBIC HEALTH INC.
measure. understand. manage.

ADDERALL XR RETURNED TO CANADIAN MARKET

OTTAWA, September 1st, 2005 – Shire BioChem Inc. has announced that Adderall XR™ (mixed salts amphetamine extended release capsules) has been returned to the Canadian market. Adderall XR™ is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The product was suspended from the Canadian market by Health Canada on February 9, 2005 due to concerns that the product may be associated with an increased risk of sudden death and stroke in children and adults taking the usual recommended doses.

The safety concerns were based on a preliminary review of international data. There have been no Canadian reports of death in patients using Adderall XR™. The Canadian product monograph will be revised to include warnings about the appropriate use of Adderall XR™, and that the product should not be used in patients with structural cardiac abnormalities.

The decision to suspend the product was re-assessed by Health Canada following the recommendations of an independent New Drug Committee appointed by Health Canada at the request of Shire BioChem.